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Abstract
Introduction: Thrombotic thrombocytopenic purpura-hemolytic uremic syndrome is a life-threatening condition
with various etiopathogeneses. Without therapy approximately 90% of all patients die from the disease.
Case presentation: We report the case of a 17-year-old Caucasian woman with widespread hematomas and
headache. Due to hemolytic anemia, thrombocytopenia, and schistocytosis, thrombotic thrombocytopenic purpura-
hemolytic uremic syndrome was suspected and plasma exchange therapy was initiated immediately. Since her
thrombocyte level did not increase during the first week of therapy, plasma treatment had to be intensified to a
twice-daily schedule. Further diagnostics showed markedly reduced activities of both ADAMTS-13 (a disintegrin and
metalloproteinase with a thrombospondin type 1 motif, member 13 - also known as von Willebrand factor-cleaving
protease) and factor H. Test results for antibodies against both proteins were positive. While plasma exchange
therapy was continued, rituximab was given once weekly for four consecutive weeks. After the last dose,
thrombocytes and activities of ADAMTS-13 and factor H increased into the normal range. Our patient improved
and was discharged from the hospital.
Conclusions: Since no clinical symptoms/laboratory findings indicated a malignant or specific autoimmune-
mediated disorder, the diagnosis made was thrombotic thrombocytopenic purpura-hemolytic uremic syndrome
due to idiopathic combined, autoantibody-mediated ADAMTS-13/factor H deficiency.
Introduction
Thrombotic thrombocytopenic purpura-hemolytic ure-
mic syndrome (TTP-HUS) can be diagnosed if a patient
has combined hemolytic anemia, schistocytosis, and
thrombocytopenia [1]. If untreated, approximately 90%
of patients die from the syndrome. A number of differ-
ent entities of TTP-HUS have been identified. In recent
years, the pathogenesis has been elucidated in several
subtypes of TTP-HUS. The ‘classical’ post-infectious
TTP-HUS develops after intestinal infection with either
Shigatoxin-producing Escherichia coli or Shigella dysen-
teriae [2,3]. However, defects of certain plasma proteins
have been shown to be associated with TTP-HUS. A
lack of ADAMTS-13 (a disintegrin and metalloprotei-
nase with a thrombospondin type 1 motif, member 13 -
also known as von Willebrand factor-cleaving protease),
a protease responsible for degrading von Willebrand fac-
tor precursors, can cause severe cases of TTP-HUS [4].
Another group of defects is characterized by comple-
ment-mediated lysis of microvascular endothelial cells in
kidney, brain, and other organs, respectively. The most
frequent defect is factor H deficiency, which accounts
for 15% of all TTP-HUS cases [5,6]. The treatment of
choice of TTP-HUS is plasma exchange [1]. This recom-
mendation results from the fact that mortality of
untreated TTP-HUS is unacceptably high. * Correspondence: d.patschan@gmail.com; peter.korsten@web.de
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ADAMTS-13/factor H deficiency.
Case presentation
A 17-year-old Caucasian woman presented to our facil-
ity with a history of fatigue, easy bruising and headache
for two weeks. The headache was diffuse, dull and did
not respond to oral ibuprofen at a dose of 400 mg up to
three times daily. There were no associated visual symp-
toms, nausea or vomiting. There was no history of
excessive menstrual bleeding, sexually transmitted dis-
ease or use of recreational or illicit drugs. The easy
bruising was attributed initially to canoeing with some
friends two days prior to admission. She had no history
of trauma, no known allergies and denied recent medi-
cation use (other than ibuprofen). Our patient lived with
her parents and a younger brother who did not have any
known illnesses, and specifically no bleeding disorders.
She was in her last year at high school and ate a normal
diet. A physical examination showed a woman of Cauca-
sian origin in a mildly obese nutritional state (64.8 kg)
and appropriate appearance for her age. Heart, lung and
abdominal examination results were unremarkable. Skin
examination results revealed hematomas of different
sizes ranging from 2.5 to 10.1 mm involving the arms,
legs, and trunk. Laboratory test results from a local hos-
pital revealed anemia with a hemoglobin level of 7.2 g/
dL (normal range 11.5 to 15 g/dL) and thrombocytope-
nia of 19 × 10
6 cells/μL (normal range 150 to 350 × 10
6
cells/μL), for which our patient was referred to our cen-
ter. Laboratory findings at the University Hospital of
Göttingen showed severe anemia (hemoglobin at 6 g/
dL), thrombocytopenia (17.7 × 10
6 cells/μL), an increase
in lactate dehydrogenase (LDH) activity (963 U/L, refer-
ence < 350 U/L), and negative haptoglobin (< 0.2 g/L,
normal range 0.45 to 2.05 g/L). Her schistocyte count
was 10‰ (< 5‰). Her complement activity was reduced
( C 30 . 7 6g / L ,n o r m a lr a n g e0 . 9t o1 . 8g / L ;C 40 . 0 6g / L ,
normal range 0.1 to 0.4 g/L).
TTP-HUS was suspected given the anemia, thrombo-
cytopenia, elevated LDH activity, non-measurable hapto-
globin, and the presence of schistocytes in the
peripheral smear. Our patient was referred to the inten-
sive care unit for immediate plasma exchange therapy.
For initial plasma exchange therapy, our patient received
250 mg prednisolone intravenously daily for three days,
combined with 0.5 L of fresh frozen plasma. Plasma
exchange therapy was started the next morning
(approximately six hours after admission). The plasma
volume to be exchanged per individual treatment ses-
sion was calculated to be 40 mL/kg. Therapy efficacy
was monitored by daily measurement of her thrombo-
cyte levels. Although plasmae x c h a n g et r e a t m e n tw a s
performed every day, her thrombocyte level decreased
further, reaching 5 × 10
6 cells/μL at day 12 after admis-
sion. There was no evidence of bacterial, viral or parasi-
tic infection. One week after admission our patient
became confused, and developed disorientation and
aggressiveness. Magnetic resonance scan results did not
show any abnormalities. A computed tomography (CT)
scan of her thorax, abdomen, and pelvis and blood tests
for anti-nuclear antibodies (ANAs), anti-neutrophil cyto-
plasmic antibodies (ANCAs), and rheumatoid factor
were performed [7]. The test results did not show any
relevant abnormality. The only relevant finding was
decreased complement activity. Around this time, the
results from further serological analysis became avail-
able, showing a dramatically reduced activity of both
ADAMTS-13 and factor H. Antibodies against the two
proteins were positively detected. Therefore, and since
increased activity of the disease was apparent, plasma
exchange therapy was intensified to a twice-daily sche-
dule. Her thrombocyte count remained stable at a very
low range over the following eight days, with a mini-
mum of 1 × 10
6 cells/μL at day 18 after the first plasma
exchange. Our patient did not receive thrombocytes or
coagulation factors. Intravenous rituximab, a chimeric
monoclonal antibody against CD20, was initiated at a
dose of 375 mg/kg/week, with four consecutive adminis-
trations [8]. At the same time, glucocorticoid therapy
was continued with 1 mg/kg daily orally. Steroids were
tapered over the following four months. Plasma
exchange treatment was continued once to twice daily
but was not performed on the days after rituximab infu-
sion. Her thrombocyte count reached its first maximum
a td a y3 6( 3 1 4×1 0
6 cells/μL) and our patient’sm e n t a l
issues resolved completely. The last of the four infusions
of rituximab was given at day 42 after admission; the
last plasma exchange was performed three days later.
Two days later, her thrombocyte count reached its sec-
ond maximum of 344 × 10
6 cells/μL. Thereafter, throm-
bocytes decreased transiently (128 × 10
6 cells/μL),
followed by an increase to 228 × 10
6 cells/μL on the day
of discharge from hospital.
Figure 1 summarizes the thrombocyte count over her
w h o l es t a yi nt h eD e p a r t m e n to fN e p h r o l o g y .O u r
patient’s renal function was not affected at any given
time and she did not exhibit any sediment abnormal-
ities. Protein analysis, performed during the first two
days after admission, showed low-grade proteinuria of
mixed (that is, glomerular and tubular) origin. The
activities of ADAMTS-13 and factor H were re-evalu-
ated before our patient was discharged. Both enzymes
were within normal ranges and antibody test results
were negative. Table 1 shows the results from the
initial blood analysis and from the day before
discharge.
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asymptomatic with normal blood counts at 12-month
follow-up. Our patient did not develop any infectious
complications during the follow-up period.
In order to identify a possible genetic background for
our patient’s disease, her two parents and brother were
screened for ADAMTS-13 and factor H activities, and
for the concentrations of the respective antibodies to
these factors. The results were completely negative (data
not shown).
Discussion
The coincidence of combined ADAMTS-13/factor H
deficiency confirms the presence of TTP-HUS. Since no
genetic background was identified to be associated with
t h ee n z y m ed e f i c i t ,t h ed i a g n o s i st ob em a d ei no u r
patient was idiopathic TTP-HUS due to combined
(autoantibody-mediated) ADAMTS-13/factor H
deficiency.
TTP-HUS can be diagnosed if a patient has combined
hemolytic anemia, schistocytosis, and thrombocytopenia
[1]. In fact, these findings legitimize immediate plasma
exchange therapy even if no other obvious cause can be
identified [1]. Such a recommendation results from the
fact that mortality of untreated TTP-HUS is unaccepta-
bly high (up to 90%). Blood samples for further diagnos-
tic steps should be drawn before the first plasma
exchange therapy. As soon as plasma exchange therapy
has been initiated, further diagnostic steps have to be
made in order to recognize diseases that can mimic
TTP-HUS. First and foremost, infectious diseases have
to be excluded. Systemic bacterial infections, and in par-
ticular sepsis are frequently associated with the presence
of schistocytes and thrombocytopenia [9]. This, in most
Figure 1 Thrombocyte count over a period of 60 days. After 12 days of plasma exchange treatments performed daily, therapy was
intensified to a twice-daily schedule. Rituximab was administered for the first time at day 20 and then the drug was administered once weekly
with a total of four dosages [8].
Table 1 Laboratory findings on the days of admission and a day before discharge
Parameter Day of admission Day before discharge
Hemoglobin (reference: 11.5 to 15.0 g/dL) 6 12
Thrombocytes (reference: 150 to 350 × 10
6 cells/μL) 17.7 228
Lactate dehydrogenase (reference: < 350 U/L) 963 237
Haptoglobin (reference: 0.45 to 2.05 g/L) < 0.2 0.69
Fragmentocytes (reference: < 5‰)1 0 < 5
Creatinine (reference: 0.55 to 1.02 mg/dL) 0.89 0.78
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tion. A subsequent lack of pro-coagulatory proteins can
cause bleeding complications with anemia, which can
also result from microvascular erythrocyte fragmenta-
tion. In some situations it may become complicated to
clearly differentiate between TTP-HUS and alternative
diagnoses. This is the case (a) in systemic lupus erythe-
matosus (SLE) with or without simultaneous anti-phos-
pholipid syndrome (APS), in (b) systemic sclerosis (SS)
with renal crisis, and (c) in malignant hypertension.
The question of whether a patient has TTP-HUS
becomes even more complicated in pregnancy. Approxi-
mately one to three in every 300 pregnant women devel-
ops HELLP (hemolysis, elevated liver enzymes, low
platelet count) syndrome [10]. Besides hemolysis and
thrombocytopenia, schistocytosis is a hallmark of
HELLP syndrome. TTP-HUS during pregnancy is
almost indistinguishable from HELLP syndrome, and
requires a completely different therapeutic approach
(plasma exchange treatment).
Next, the different types of ‘classical’ TTP-HUS have
to be taken into consideration. Post-infectious TTP-
HUS, either induced by enterohemorrhagic E. coli (sero-
type O 157 or O 104) or by S. dysenteriae,i sm o r ef r e -
quently seen in children than in adults [11]. It does not
require plasma exchange treatment. Further perpetuat-
ing factors in TTP-HUS are deficiencies of complement
regulatory proteins (factor H, factor I, and decay-accel-
erating factor [5]). It has been considered that impaired
inhibition of complement proteins may trigger comple-
ment-induced damage of host cells. In this process,
endothelial damage may be responsible for microthrom-
bogenesis in small arteries and capillaries, which subse-
quently induces thrombocytopenia, hemolysis, and
schistocytosis. Finally, in the setting of reduced
ADAMTS-13 activity, other causes of diminished
enzyme activity not related to TTP-HUS have to be
ruled out. In fact, low ADAMTS-13 is not specific for
TTP-HUS [4]. Reduced concentrations of the protein,
leading to increased circulating levels of ultra-large von
Willebrand factor (ULVWF) have been shown in a sub-
set of patients with sepsis. Impaired von Willebrand fac-
tor cleaving activity of ADAMTS-13 was also
demonstrated in patients with metastasizing malignant
tumors. In addition, systemic connective tissue diseases
are other conditions that can be associated with low but
detectable levels of ADAMTS-13. Figure 2 summarizes
the differential diagnosis of TTP-HUS.
Although a number of different entities of TTP-HUS
have been identified, which require different therapeutic
approaches, it is mandatory to initiate plasma exchange
treatment as soon as thrombocytopenia and hemolytic
anemia with simultaneous schistocytosis are diagnosed
[1]. The only exception is suspected TTP-HUS in
children who have had diarrhea prior to diagnosis. In
these cases, post-infectious TTP-HUS or childhood Shi-
gatoxin-associated TTP-HUS must be assumed. Thera-
peutic measures include fluid administration and dialysis
treatment in severe cases. In most children Shigatoxin-
associated TTP-HUS recovers spontaneously. In adults,
the situation with Shigatoxin-associated TTP-HUS is
quite different. Although the pathogenesis is the same,
renal and neurological involvement are usually more
severe [12]. In addition, older patients have a mortality
rate of approximately 90%, which is at least 15-fold
higher than in children [13]. Even today, there are no
prospective, randomized trial results available that
resolve the question of whether plasma exchange ther-
apy, either by simply infusing plasma or by plasma
exchange, may be of benefit in Shigatoxin-associated
TTP-HUS in adults [14]. Regardless, plasma exchange
therapy can serve as an option, since comparative ana-
lyses of patients treated without plasma versus patients
treated with plasma suggest a significantly decreased
overall mortality rate in the latter [14]. Therefore, Rug-
genenti and colleagues [14] recommended plasma infu-
sion or exchange in adult patients with Shigatoxin-
associated TTP-HUS if severe renal insufficiency is pre-
sent and/or central nervous system is involved.
In TTP-HUS caused by either ADAMTS-13 or by
complement deficiency, plasma exchange therapy is the
treatment of choice. Initially, plasma exchange therapy
should be performed daily and treatment should be
monitored by measuring the thrombocyte count. In
most cases, initial plasma administration should be
accompanied by glucocorticoids. Whether and when the
patient will respond to treatment is difficult to predict.
In cases without any response to daily plasma exchange
therapy, the regimen can be intensified to a twice-daily
schedule [14]. Thus, recycling of infused plasma is mini-
mized. Another alternative is to apply the cryosuperna-
tant fraction of plasma. The cryosupernatant remains
after removal of a cryoprecipitate, containing the largest
amount of ULVWF, fibrinogen, fibronectin, and fibrin
split products, respectively. This approach has success-
fully been used in a few patients with refractory TTP-
HUS but its use is limited by restricted availability.
If intensified plasma exchange therapy or the adminis-
tration of cryosupernatant does not sufficiently control
disease activity, further pharmaceutical interventions can
be initiated. First, and as already pointed out, glucocorti-
coids are widely used for initial therapy. Perotti and col-
leagues found remission rates of approximately 75% in
patients with TTP-HUS who received combined treat-
ment with intravenous methylprednisolone (2 mg/kg/
day) and daily plasma exchange. However, to date, no
systematic clinical trial has compared this regimen with
plasma exchange alone. Patients with milder
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no neurological symptoms, may respond to glucocorti-
coids alone [15]. Another drug that has occasionally
been used in refractory or relapsing TTP-HUS is vin-
cristine. Cyclophosphamide has been used as both daily
dosing and pulsed therapy [16]. The common character-
istic of drugs such as vincristine and cyclophosphamide
is their potency to suppress the activity of lymphocytes.
This mechanism is most likely responsible for the effec-
tiveness of the substances in the treatment of refractory
TTP-HUS. It must be assumed that suppression of
autoantibody-producing B cell clones and of their
respective descendants, the plasma cells, inhibits further
autoantibody production and thus further immune-
mediated depletion of ADAMTS-13 and complement
regulatory proteins, respectively. The same rationale
legitimates the administration of rituximab. The first
mention of rituximab as a therapeutic option in cases of
refractory TTP-HUS was published in 2002 [17]. Two
patients, both women, with TTP-HUS refractory to plas-
mapheresis, glucocorticoids, and vincristine responded
to the treatment after adding rituximab. Since then, the
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Figure 2 Differential diagnosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndrome (TTP-HUS).
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Page 5 of 7drug has been successfully used in resistant TTP-HUS
with relevant response rates [18]. The mechanism of
action of rituximab appears to be suppression of anti-
body-producing B cells [19], but effects on regulatory T
cells have also been described which might attenuate
the inflammatory response in those cases that are not
merely triggered by antibodies [20]. An even newer ther-
apeutic tool is the substance eculizumab. The drug acts
as inhibitor of complement factor C5, which is activated
by cleaving through the factor complex C3bBbC3b. Ecu-
lizumab has initially been used to treat patients with
paroxysmal nocturnal hemoglobinuria (PNH) [21]. In
2008, Nürnberger and colleagues reported the first suc-
cessful use of the drug in atypical (complement-
mediated) hemolytic-uremic syndrome [22]. Since then,
the substance has been administered with convincing
response rates in patients who had an atypical type of
TTP-HUS [23-26]. It should be noted that the mode of
action of eculizumab in TTP-HUS is most likely not the
inhibition of complement-induced red blood cell lysis
but the inhibition of complement-mediated endothelial
cell damage with subsequent microthombus formation.
Our patient showed combined deficiency of
ADAMTS-13 and complement factor H. With regard to
the complement defect, eculizumab was initially dis-
cussed as a therapeutic alternative. But, with the pre-
sence of autoantibodies against both proteins, a B-cell
depleting therapy seemed much more promising. In fact,
our patient responded with complete and, to date, stable
remission. Regarding the heterogenous nature of the
defect, any prediction of potential relapses is impossible.
Conclusions
Our patient had idiopathic combined, autoimmune-
mediated ADAMTS-13/factor H deficiency. Although,
to the best of our knowledge, such a defect has never
been reported before in the literature, it is important to
recognize that therapy resistance in TTP-HUS can result
from combined deficiencies in plasmatic regulators.
Regardless, any secondary cause of TTP-HUS must be
ruled out before drugs such as rituximab and eculizu-
mab are administered to these patients. The use of
rituximab in patients without any evidence of autoanti-
body production cannot be recommended. Regular fol-
low-up with patients is needed to detect infections
shortly after treatment, and in the long-term to detect
secondary malignancies or relapses.
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